"As many as three-fourths of surveyed rheumatologists indicated they would be likely to prescribe Krystexxa within the first 12 months of commercial availability. The agent's rapid onset of action, ability to resolve tophi and potency in lowering uric acid levels were cited as its most important advantages"
The side effects are bad though, and they are prescribing it to only the worse patients. And only for a short period of time. This has turned out to be worse than I had ever thought possible, in terms of fewer patients being prescribed. It appears the J-code will do much less than most of us had anticipated.
You didn't do any DD at all, did you? If this is worse than you thought, then you should have actually researched the drug BEFORE you invested in the company. You are the type of investor that gets fleeced because you know nothing about your investment, yes?
By the way, 3% of 5-6 million is 150K-180K patients. I find that number intriguing...
This investment is going to be longer term than I had anticipated. But you know what? The development of new goods and services is the proper use of capital, which increases wealth (hopefully my own as well) and prosperity. So I am liking this investment more and more, despite it's short term problems...
The arrival of the "J code" in January will cause the real beginning of the boom in sales. As much as physicians want to use Krystexxa, money talks and nobody wants to "lay out" a hundred grand per patient, or whatever it is.
This product will be successful and will boom, worldwide. It's just going to take a little more patience.